December 21, 2020 “Dream with Ryvu” – a corporate movie by Ryvu Therapeutics
Read More
December 3, 2020 Ryvu Therapeutics publishes MNK1/2 kinase inhibitors research paper in the European Journal of Medicinal Chemistry
Read More
December 1, 2020 Three Posters on SEL24/MEN1703 including Pharmacodynamic Data from the Dose Escalation Part of DIAMOND-01 Trial to be published at American Society of Hematology (ASH) Annual Meeting
Read More
November 26, 2020 Solebury Trout Talks Podcast: Interview with Pawel Przewiezlikowski
Read More
November 23, 2020 Ryvu Therapeutics Appoints Kamil Sitarz as Chief Operating Officer and Member of the Management Board
Read More
November 19, 2020 Ryvu Therapeutics Reports Q3 2020 Financial Results
Read More
November 12, 2020 Ryvu Therapeutics at Jefferies Virtual London Healthcare Conference
Read More
October 19, 2020 Ryvu Therapeutics at BIO-Europe 2020
Read More
October 15, 2020 Ryvu Therapeutics Announces Abstract Accepted for Presentation at the Society for Immunotherapy of Cancer 35th Anniversary Annual Meeting (SITC 2020)
Read More
September 16, 2020 First patient dosed in Europe within the Expansion Cohort of Phase I/II Clinical Study of SEL24/MEN1703 in Acute Myeloid Leukemia
Read More
Posts navigation
